Accelerate Diagnostics is an in vitro diagnostics company. The company's Accelerate Pheno? system utilizes genotypic technology to identify (ID) infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial and fungal cells are resistant or susceptible to a particular antimicrobial. The Accelerate PhenoTest? BC Kit, which is the test kit for the system, provides ID and AST results for patients suspected of bacteremia or fungemia, both conditions with morbidity and mortality risk. The Accelerate Pheno? system comprises of a robotic pipettor for fluidic manipulation, an optical system, and an imaging system.

ADMA Biologics is a biopharmaceutical and immunoglobulin company that manufactures, markets and develops plasma-derived biologics for the treatment of immune deficiencies and the prevention and treatment of certain infectious diseases. The company's marketed products consist of: Nabi-HB, which is indicated for the treatment of acute exposure to blood containing Hepatitis B surface antigen; and Bivigam, which is indicated for the treatment of primary humoral immunodeficiency. The company is also developing a pipeline of plasma-derived therapeutics, including its key pipeline product candidate, RI-002, for the treatment of Primary Immune Deficiency Disease.

Inspirit Energy Holding is engaged in the development and commercializing of micro Combined Heat and Power (mCHP) boiler for use in commercial and residential markets. The mCHP boiler is powered by natural gas and designed to produce hot water (for domestic hot water or central heating) and a simultaneous electrical output that can be used locally or fed back into the National Grid.

MacroGenics discovers and develops antibody-based therapeutics to modulate the human immune response for the treatment of cancer. The company has a pipeline of product candidates in human clinical testing, including immuno-oncology programs, that have been created using its proprietary antibody-based technology platforms. The company is developing product candidates that target various tumor-associated antigens, including HER2. The company is also developing a franchise of molecules that target programmed cell death protein 1 (PD-1). The company is developing two bispecific DART product candidates that engage PD-1 and lymphocyte-activation gene 3, as well as PD-1 and cytotoxic T-lymphocyte-associated protein 4.

Penns Woods Bancorp is a bank holding company. Through its subsidiaries, Jersey Shore State Bank (JSSB) and Luzerne Bank (collectively, the Banks), the company is engaged in commercial and retail banking which includes the acceptance of time, savings, and demand deposits, the funding of commercial, consumer, and mortgage loans, and safe deposit services. The Banks provide insurance, securities brokerage services, annuity and mutual fund investment products, and financial planning through JSSB's subsidiary, The M Group, Inc. Services provided by the Banks include accepting time, demand and savings deposits including Super NOW accounts, money market accounts, and fixed rate certificates of deposit.

Safehold is a holding company. Through its subsidiaries, the company operates its business through one segment by acquiring, managing and capitalizing ground leases. Ground leases generally represent the ownership of land underlying commercial real estate properties, which are leased on a long-term basis (base terms are 30 to 99 years, often with tenant renewal options) by the land owner to a tenant that owns and operates the building on top of the land, or what the company refer to as a Safehold?.

Savara is an orphan lung disease company. The company's drug development pipeline comprises Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor in development for pulmonary alveolar proteinosis and in development for nontuberculous mycobacterial lung infection; and AeroVanc, an inhaled vancomycin for treatment of persistent methicillin-resistant Staphylococcus aureus lung infection in individuals living with cystic fibrosis.

Sensient Technologies is a manufacturer and marketer of colors, flavors and fragrances. The company's three reportable segments are: Flavors & Fragrances Group, which develops, manufactures, and supplies flavor and fragrance systems for the food, beverage, personal care, and household-products industries; Color Group, which provides natural and synthetic color systems for use in foods, beverages, pharmaceuticals, and nutraceuticals, colors and other ingredients for cosmetics; and Asia Pacific Group, which provides a range of products from its Flavors & Fragrances Group and Color Group, as well as products developed by regional technical teams to appeal to local preferences.